Patents Examined by A M Ford
-
Patent number: 7402319Abstract: The present invention is a natural, cell-free tissue replacement that does not require difficult or extensive preparation made by washing tissue replacement in a solution including one or more sulfobetaines and an anionic surface-active detergent and washing the tissue replacement in serial solutions of the buffered salt to remove excess detergent. The natural, cell-free tissue replacement may be a nerve graft that supports axonal regeneration, guides the axons toward the distal nerve end and/or is immunologically tolerated. Other forms of the invention are a composition and kit prepared by the method of making a native, cell-free tissue replacement. The present invention may be modified for use in diagnostic, therapeutic, and prophylactic applications.Type: GrantFiled: September 26, 2003Date of Patent: July 22, 2008Assignee: Board of Regents, The University of Texas SystemInventors: Christine Schmidt, Terry Hudson
-
Patent number: 7384630Abstract: Novel methods, tissues and compositions for increasing the pancreatic mass of a mammalian recipient including harvesting immature pancreatic tissue from a mammalian donor and transplanting said tissue into the peritoneal cavity of a mammalian recipient under conditions that allow the pancreatic tissue to become vascularized and mature, thereby developing a functioning chimeric, endocrine pancreas that produces at least insulin in the recipient. The invention also includes mammalian immature pancreatic tissue adapted for transplantation into the peritoneal cavity of a mammalian recipient for increasing the pancreatic mass of the mammalian recipient as well as methods and compositions for treatment of the pancreatic tissue, recipient immunosuppression and recipient co-stimulatory blockade.Type: GrantFiled: March 24, 2003Date of Patent: June 10, 2008Assignee: Washington UniversityInventor: Marc R. Hammerman
-
Patent number: 7381404Abstract: The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.Type: GrantFiled: July 1, 2003Date of Patent: June 3, 2008Assignees: The Regents of the University of California, California Institute of TechnologyInventors: Daniel M. Schwartz, Scott Fraser, Robert H. Grubbs, Justin P. Gallivan, Changjun Yu
-
Patent number: 7371410Abstract: A bone graft substitute composition can include essentially of calcium sulfate, a mixing solution, and a plasticizing substance. A bone graft substitute composition can include calcium sulfate, demineralized bone matrix, cancellous bone, a plasticizing substance, and a mixing solution.Type: GrantFiled: January 30, 2002Date of Patent: May 13, 2008Assignee: Wright Medical Technology, Inc.Inventor: Donald W. Petersen
-
Patent number: 7371409Abstract: A bone graft substitute composition can include essentially of calcium sulfate, a mixing solution, and a plasticizing substance. A bone graft substitute composition can include calcium sulfate, demineralized bone matrix, cancellous bone, a plasticizing substance, and a mixing solution.Type: GrantFiled: September 6, 2001Date of Patent: May 13, 2008Assignee: Wright Medical Technology, Inc.Inventors: Donald W. Petersen, Barbara E. Blum
-
Patent number: 7371575Abstract: The present invention concerns methods for the ex vivo formation of mammalian bone and subsequent uses of the bone. A critical and distinguishing feature of the present invention are defined tissue culture conditions and factors resulting in the formation of bone cell spheroids. The invention also provides for methods of implanting into subjects the ex vivo formed bone. Also described are methods for genetically altering the bone cell spheroids to affect bone formation, identification of candidate modulators of bone formation, and identification of genes involved in bone formation.Type: GrantFiled: June 8, 2004Date of Patent: May 13, 2008Assignee: The Regents of The University of MichiganInventors: Sujata Kale, Michael W. Long
-
Patent number: 7371408Abstract: A bone graft substitute composition comprising calcium sulfate; a mixing solution selected from the group consisting of sterile water, sodium chloride, phosphate buffered saline, potassium chloride, and sodium sulfate; and a plasticizing substance selected from the group consisting of carboxymethylcellulose, polyvinyl alcohol, methycellulose, and hydroxypropyl methylcellulose.Type: GrantFiled: June 7, 1999Date of Patent: May 13, 2008Assignee: Wright Medical Technology, Inc.Inventors: Donald W. Petersen, Warren O. Haggard, Donald A. Randolph, Cary P. Hagan
-
Patent number: 7354764Abstract: In a method for culturing cells (2), according to which cells (2) are introduced into a cell culture chamber in order to form a cellular layer, the chamber being configured inside a carrier structure (1). The shape and size of the carrier structure (1) correspond to the shape that is to be formed by the cells (2), such as an implant or a prosthesis. Nutrients and oxygen are fed to the carrier structure (1). The exterior of the carrier structure (1) is provided with a boundary membrane (4) that is impermeable to cells.Type: GrantFiled: July 28, 2003Date of Patent: April 8, 2008Assignee: Bionethos HoldingInventor: Augustinus Bader
-
Patent number: 7348135Abstract: An assay for assessing the permeability of mitochondrial membranes is provided. The assay is based on enzymatic reactions that produce a detectable signal in the presence of intra-mitochondrial compounds. In some embodiments, the intra-mitochondrial compounds may be reduced and/or oxidized nicotinamide adenine dinucleotides (i.e., NADH and NAD+, respectively). The assay may optionally be provided in the form of a kit, and may further be useful in the discovery and interrogation of compounds that may serve to inhibit pathologic increase in mitochondrial membrane permeability, which is associated with numerous and varied mammalian disease.Type: GrantFiled: August 26, 2004Date of Patent: March 25, 2008Assignee: University of MarylandInventors: Tibor Kristian, Gary Fiskum
-
Patent number: 7343402Abstract: In an MFP apparatus according to the present invention, a communication I/F 34 communicates with at least another MFP apparatus or a server via a network. A storage section 37 stores the data received via the communication I/F 34. Then, a CPU 21 performs control in such a manner that it organizes information about customized data in the form of a data file, applies to the server via the communication section for the registration of the data file, and transmits the customize data to another MFP apparatus via the communication section on the basis of the request of the server, or that it requests another MFP apparatus to acquire customized data and stores the customized data transmitted on the basis of the request into the storage section.Type: GrantFiled: March 10, 2003Date of Patent: March 11, 2008Assignees: Kabushiki Kaisha Toshiba, Toshiba Tec Kabushiki KaishaInventor: Takahiro Hagiwara
-
Patent number: 7340519Abstract: A method of configuring a network element such that a Virtual Private Network (VPN) site can connect to the network element is disclosed. An interface on a Provider Edge (PE) router is configured in restricted mode. A request is received from the interface to authenticate a user associated with a VPN requesting to connect to the interface. A determination is made as to whether the user is authorized to submit requests to the interface. If the user is authorized, an activation request is received from the interface to allow the VPN can connect to the interface. A determination is made as to whether the user is authorized to connect to the interface via the VPN. If the user is authorized, VPN site parameters are configured at the PE router and the PE router is configured in unrestricted mode.Type: GrantFiled: March 5, 2003Date of Patent: March 4, 2008Assignee: AT&T Corp.Inventors: Joseph Golan, Joseph Thomas O'Neil
-
Patent number: 7326570Abstract: Provided are methods and compositions for constructing stable mammalian embryonic epithelial tissues and organs as well as constructing kidney tissue, and treating renal failure. Disclosed are methods of using an active epithelial growth factor having the capability of effectuating induction of growth and morphognesis is cells.Type: GrantFiled: June 27, 2003Date of Patent: February 5, 2008Assignee: The Regents of the University of CaliforniaInventors: Sanjay Kumar Nigam, Hiroyuki Sakurai, Kevin T. Bush
-
Patent number: 7323333Abstract: The subject invention pertains to materials and methods for inhibiting process formation and extension by cells in culture. The subject invention further includes cultures of process-forming cells wherein formation and extension of processes have been inhibited. In another aspect, the subject invention concerns methods of transplantation using process-forming cells that have been cultured by the process-inhibiting methods of the invention.Type: GrantFiled: March 31, 2004Date of Patent: January 29, 2008Assignees: University of South Florida, University of ChileInventors: Pablo Caviedes, Raul Caviedes, Thomas B. Freeman, Juan A. Asenjo, Barbara A. Andrews, Dario SepĂșlveda, Christian Arriagada, Julio Salazar Rivera
-
Patent number: 7320020Abstract: Email senders may transmit emails over the internet to a mail server that handles emails for a plurality of users (clients). The mail server may use a spam filter to remove the spam and then transmit the filtered emails to the addressed clients. The spam filter may use a white list, black list, probability filter and keyword filter. The probability filter may use a user mail corpus and a user spam corpus for creating a user probability table that lists tokens and the probability that an email is a spam if the email contains the token. The probability filter may also use a general mail corpus and a general spam corpus for creating a general probability table that. Tokens of incoming emails may be searched for in the user probability table, and if not found, the general probability table to calculate the probability that the email is a spam.Type: GrantFiled: April 17, 2003Date of Patent: January 15, 2008Assignee: The Go Daddy Group, Inc.Inventors: Michael Christopher Chadwick, Adam Thomas Sink, Blake Schwendiman
-
Patent number: 7300793Abstract: A method for the prevention of the adhesion of particles, in particular cells and cellular components in solution to surfaces, characterized in that to the solution is added at least one polyalcohol.Type: GrantFiled: July 17, 2002Date of Patent: November 27, 2007Assignee: Evotec Technologies GmbHInventor: Gabriele Gradl
-
Patent number: 7294352Abstract: Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation.Type: GrantFiled: October 30, 2003Date of Patent: November 13, 2007Assignee: Biora BioEx ABInventors: Stina Gestrelius, Lars Hammarström, Petter Lyngstadaas, Christer Andersson, Ivan Slaby, Tomas Hammargren
-
Patent number: 7294334Abstract: Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle using a combination of therapies. The method may include the introduction of structurally reinforcing agents. In other embodiments, agents may be introduced into a ventricle to increase compliance of the ventricle. The prevention of remodeling may include the prevention of thinning of the ventricular infarct zone. Another embodiment includes the reversing or prevention of ventricular remodeling with electro-stimulatory therapy. The unloading of the stressed myocardium over time effects reversal of undesirable ventricular remodeling. These therapies may be combined with structurally reinforcing therapies. In other embodiments, the structurally reinforcing component may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.Type: GrantFiled: March 16, 2004Date of Patent: November 13, 2007Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Eugene T. Michal, Jeffrey Ross
-
Patent number: 7291500Abstract: In order to grow an object to be cultivated or grown, a growth object is encapsulated in a vessel, and the growth object is grown without substantial influence of gravity.Type: GrantFiled: May 18, 2005Date of Patent: November 6, 2007Assignees: Mitsubishi Heavy Industries, Ltd.Inventors: Masaru Uemura, Jun-ichiro Gyotoku, Makoto Asashima
-
Patent number: 7291179Abstract: Bone graft substitute compositions and methods of making the compositions are disclosed. In some embodiments, a method of making a composition includes contacting a mixing solution with a first mixture having calcium sulfate hemihydrate and a plasticizing material to form a second mixture; waiting a predetermined period of time after forming said second mixture; and then contacting demineralized bone with the second mixture to form the composition. A composition can be formed from a kit including a first mixture having calcium sulfate hemihydrate and a plasticizing substance, a second mixture having demineralized bone, and a mixing solution. The first and second mixtures and the mixing solution are unblended.Type: GrantFiled: May 30, 2003Date of Patent: November 6, 2007Assignee: Wright Medical Technology, Inc.Inventors: Leasa C. Miller, Kelly Coupe Richelsoph, Jon P. Moseley
-
Patent number: 7257644Abstract: Providing presence tracking of nodes of a logical network in a distributed computing system. Each node in a logical network tracks the presence of all other nodes on the network. This presence information is used by the protocol to optimize bandwidth utilization of the shared physical media, by not attempting to communicate with a device that does not appear to be or is unlikely to be present. In one embodiment, the presence tracking is applied to a power line carrier (PLC) physical media because of PLC's low-bandwidth characteristics, low baud rate characteristics and the widespread usage of plugged-in devices, the presence of which on the network is generally more transient by nature.Type: GrantFiled: September 19, 2002Date of Patent: August 14, 2007Assignee: Microsoft CorporationInventors: Guillaume Simonnet, Harry S. Pyle